Literature DB >> 21264531

EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray.

Donggen Liu1, Jiehua He, Zhongyu Yuan, Shusen Wang, Roujun Peng, Yanxia Shi, Xiaoyu Teng, Tao Qin.   

Abstract

The aim of this study was to analyze the prognostic value of EGFR expression for patients with triple-negative breast cancer (TNBC). Clinical data of these patients were collected and analyzed, and immunohistochemical staining for EGFR was performed on tissue microarrays of operable breast cancer from 287 patients with TNBC, who were treated at Sun Yat-sen University Cancer Center from January 1995 to December 2008. EGFR expression was found in 36.2% of the cases with TNBC. A significant correlation was found between EGFR expression and disease-free survival (DFS). Univariated analysis indicated that EGFR expression had a significant prognostic value in TNBC patients, whereas multivariate analysis indicated that EGFR was a significant independent prognostic factor of DFS (P = 0.011) in all patients. Our results suggested that EGFR was an independent prognostic factor of DFS in patients with TNBC. Therefore, EGFR could become a good therapeutic target in the treatment of TNBC.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21264531     DOI： 10.1007/s12032-011-9827-x

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  20 in total

1.  Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status.

Authors:  D Torregrosa; P Bolufer; A Lluch; J A López; E Barragán; A Ruiz; V Guillem; B Munárriz; J García Conde
Journal:  Clin Chim Acta       Date:  1997-06-27       Impact factor: 3.786

2.  The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

Authors:  Lisa A Carey; E Claire Dees; Lynda Sawyer; Lisa Gatti; Dominic T Moore; Frances Collichio; David W Ollila; Carolyn I Sartor; Mark L Graham; Charles M Perou
Journal:  Clin Cancer Res       Date:  2007-04-15       Impact factor: 12.531

3.  Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer.

Authors:  Shinichi Tsutsui; Shinji Ohno; Shigeru Murakami; Yoichi Hachitanda; Shinya Oda
Journal:  Breast Cancer Res Treat       Date:  2002-01       Impact factor: 4.872

4.  Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Authors:  Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

Review 5.  Triple-negative breast cancer: risk factors to potential targets.

Authors:  Bryan P Schneider; Eric P Winer; William D Foulkes; Judy Garber; Charles M Perou; Andrea Richardson; George W Sledge; Lisa A Carey
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

6.  Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer.

Authors:  J B Arnes; L R Bégin; I Stefansson; J-S Brunet; T O Nielsen; W D Foulkes; L A Akslen
Journal:  J Clin Pathol       Date:  2008-08-04       Impact factor: 3.411

7.  Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases.

Authors:  Nancy U Lin; Elizabeth Claus; Jessica Sohl; Abdul R Razzak; Amal Arnaout; Eric P Winer
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

Review 8.  The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients.

Authors:  J G Klijn; P M Berns; P I Schmitz; J A Foekens
Journal:  Endocr Rev       Date:  1992-02       Impact factor: 19.871

9.  Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients.

Authors:  David S P Tan; Caterina Marchió; Robin L Jones; Kay Savage; Ian E Smith; Mitch Dowsett; Jorge S Reis-Filho
Journal:  Breast Cancer Res Treat       Date:  2007-10-06       Impact factor: 4.872

10.  Breast cancer subtypes and survival in patients with brain metastases.

Authors:  Byung-Ho Nam; Sun Young Kim; Hye-Sook Han; Youngmee Kwon; Keun Seok Lee; Tae Hyun Kim; Jungsil Ro
Journal:  Breast Cancer Res       Date:  2008-02-28       Impact factor: 6.466
View more
  37 in total

1.  MEK inhibitor effective against proliferation in breast cancer cell.

Authors:  Yan Zhou; Hai-Yan Hu; Wei Meng; Ling Jiang; Xing Zhang; Jing-Jing Sha; Zhigang Lu; Yang Yao
Journal:  Tumour Biol       Date:  2014-06-18

Review 2.  A perspective on anti-EGFR therapies targeting triple-negative breast cancer.

Authors:  Katsuya Nakai; Mien-Chie Hung; Hirohito Yamaguchi
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

3.  Paclitaxel induces apoptosis and reduces proliferation by targeting epidermal growth factor receptor signaling pathway in oral cavity squamous cell carcinoma.

Authors:  Jing Hu; N A Zhang; Ronglin Wang; Fei Huang; Guang Li
Journal:  Oncol Lett       Date:  2015-07-16       Impact factor: 2.967

4.  BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.

Authors:  Katerina Bouchalova; Marek Svoboda; Gvantsa Kharaishvili; Jana Vrbkova; Jan Bouchal; Radek Trojanec; Vladimira Koudelakova; Lenka Radova; Karel Cwiertka; Marian Hajduch; Zdenek Kolar
Journal:  Tumour Biol       Date:  2015-01-24

5.  Toxicity and efficacy evaluation of multiple targeted polymalic acid conjugates for triple-negative breast cancer treatment.

Authors:  Jose Portilla-Arias; Rameshwar Patil; Hui Ding; Julia Y Ljubimova; Satoshi Inoue; Janet L Markman; Arthur Rekechenetskiy; Bindu Konda; Pallavi R Gangalum; Alexandra Chesnokova; Alexander V Ljubimov; Keith L Black; Eggehard Holler
Journal:  J Drug Target       Date:  2013-09-16       Impact factor: 5.121

Review 6.  Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer.

Authors:  Kyu Sic You; Yong Weon Yi; Jeonghee Cho; Jeong-Soo Park; Yeon-Sun Seong
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-18

Review 7.  Biomarkers in triple negative breast cancer: A review.

Authors:  Budhi S Yadav; Priyanka Chanana; Swaty Jhamb
Journal:  World J Clin Oncol       Date:  2015-12-10

8.  Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells.

Authors:  Somaira Nowsheen; Tiffiny Cooper; Jennifer A Stanley; Eddy S Yang
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

9.  Chemotherapeutic Potential of 2-[Piperidinoethoxyphenyl]-3-Phenyl-2H-Benzo(b)pyran in Estrogen Receptor- Negative Breast Cancer Cells: Action via Prevention of EGFR Activation and Combined Inhibition of PI-3-K/Akt/FOXO and MEK/Erk/AP-1 Pathways.

Authors:  Ruchi Saxena; Vishal Chandra; Murli Manohar; Kanchan Hajela; Utsab Debnath; Yenamandra S Prabhakar; Karan Singh Saini; Rituraj Konwar; Sandeep Kumar; Kaling Megu; Bal Gangadhar Roy; Anila Dwivedi
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

10.  Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer.

Authors:  Nathan Simon; Antonella Antignani; Robert Sarnovsky; Stephen M Hewitt; David FitzGerald
Journal:  J Natl Cancer Inst       Date:  2016-04-13       Impact factor: 11.816
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.